Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07552831

Trapeziometacarpal Joint Arthroplasty Versus Trapeziectomy for Thumb Carpometacarpal Osteoarthritis

Thumb carpometacarpal osteoarthritis is common and may cause severe pain and functional limitation. Trapeziectomy is widely used, whereas prosthetic arthroplasty may offer faster early recovery. However, detailed information on early postoperative and long-term radiological outcomes remains limited.

This is a single-centre, blinded randomised controlled trial at Sahlgrenska University Hospital, Gothenburg, Sweden. Adults aged 18-69 years with symptomatic thumb carpometacarpal osteoarthritis (Eaton grade 2-3) refractory to at least 3 months of non-operative treatment will be randomised 1:1 to trapeziometacarpal prosthetic arthroplasty or trapeziectomy. The primary outcome is day-by-day pain (registration on a numeric rating scale NRS, 0-10). Secondary outcomes include day-by-day analgesic consumption for 90 days, orthosis use after cast removal, patient-reported function (HQ-8, QuickDASH, and Nelson score) at 30, 45, 60, 75 and 90 days, assessor-measured range of motion and strength at 45 and 90 days, and long-term clinical follow-up at 6 months and 1, 2, 5 and 10 years. Cone beam computed tomography will be obtained in the arthroplasty group at 1 week postoperatively as reference and at 6 months and 1, 2, 5 and 10 years to assess implant position, migration and loosening. The target sample size is 64 participants (32 per group), providing 95% power to detect a 1-point between-group difference on the pain scale. Analyses will follow the intention-to-treat principle.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Aim and objectives The primary aim is to compare early postoperative pain trajectories after CMC-1 arthroplasty versus trapeziectomy for symptomatic thumb carpometacarpal osteoarthritis, using day-by-day patient-reported pain measurements during the first 90 postoperative days.

Secondary aims are to compare:

(i) Daily analgesic consumption during the first 90 postoperative days (ii) Orthosis use after cast removal (iii) Patient-reported hand/upper limb function using HQ-8, QuickDASH and Nelson score (iv) Blinded clinical measures of thumb range of motion, grip strength and pinch strength (v) Long-term clinical outcomes up to 10 years. Additionally, in the arthroplasty group, a long-term aim is to evaluate migration and radiological signs of implant loosening using cone beam computed tomography (CBCT). Similarly, in the trapeziectomy group, CBCT will be used to monitor and quantify metacarpal 1 proximal migration.

This protocol has been prepared in accordance with SPIRIT 2025 guidance [18], and includes a PRO EDI participant characteristics (Table 1).

Trial design This is a single-centre, assessor-blinded randomised controlled trial (RCT) with 1:1 allocation to prosthetic CMC-1 arthroplasty or trapeziectomy.

Study setting The study will be conducted at the Hand Surgery Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden. All operations will be performed by surgeons experienced in both techniques at least level 3 according to Giddins-Tang classification [19] and have at minimum overcome the previously described learning curve thresholds [20,21].

Eligibility criteria

Inclusion criteria

  • Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and/or corticosteroid injections).
  • Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-4.
  • For Eaton grade 2, age ≥50 years.
  • Age 18-69 years.
  • Provision of written informed consent.

Exclusion criteria

  • Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint).
  • Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis).
  • Post-traumatic thumb carpometacarpal osteoarthritis.
  • Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand.
  • Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus).
  • Osteoporosis/osteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty).
  • Ongoing systemic corticosteroid treatment.
  • Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis).
  • Cognitive impairment preventing reliable participation.
  • Ongoing, or suspected ongoing, alcohol or drug misuse.
  • Insufficient Swedish language proficiency to complete the questionnaires.

Participant identification, recruitment and consent Potential participants will be identified among patients referred for surgical evaluation of symptomatic thumb carpometacarpal osteoarthritis at the study site. Eligible patients will receive verbal and written information about the study. Written informed consent will be obtained before any study-specific data collection.

At baseline, participants will complete the HQ-8, QuickDASH and Nelson score questionnaires. Baseline demographic characteristics will be recorded in line with the PRO

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and/or corticosteroid injections).
  • Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-3.
  • For Eaton grade 2, age ≥50 years.
  • Age 18-69 years.
  • Provision of written informed consent.

Exclusion criteria

  • Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint).
  • Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis).
  • Post-traumatic thumb carpometacarpal osteoarthritis.
  • Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand.
  • Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus).
  • Osteoporosis/osteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty).
  • Ongoing systemic corticosteroid treatment.
  • Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis).
  • Cognitive impairment preventing reliable participation.
  • Ongoing, or suspected ongoing, alcohol or drug misuse.
  • Insufficient Swedish language proficiency to complete the questionnaires.

Treatment and study plan

trapeziometacarpal arthroplasty

Procedure

Participants allocated to arthroplasty will undergo implantation of the Touch® CMC-1 prosthesis according to routine practice at the study site. Surgery will be performed by experienced hand surgeons. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free.

Trapeziectomy

Procedure

Participants allocated to trapeziectomy will undergo surgical excision of the trapezium without tendon interposition according to routine practice at the study site. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free

Primary outcomes

  1. Pain level

    Time frame: daily for three months

    Patient-reported pain at the thumb base, measured on a 0-10 numeric rating scale (0 = no pain, 10 = worst imaginable pain).

Secondary outcomes

  1. Analgesics used

    Time frame: daily for three months

    Daily registration of analgesic consumption

  2. Use of Orthosis

    Time frame: Daily for three months

    • Orthosis use and perceived importance recorded weekly after cast removal
  3. Patient-reported thumb symptoms

    Time frame: at 30, 45, 60, 75 and 90 postoperative days

    measured with Nelson score (a disease specific questionnaire)

  4. Patient-reported upper extremity function

    Time frame: at 30, 45, 60, 75 and 90 postoperative days

    measured with QuickDASH questionnaire

  5. Patient-reported hand function

    Time frame: at 30, 45, 60, 75 and 90 postoperative days

    measured with HQ-8 questionnaire

  6. Range of motion

    Time frame: at 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.

    Objective thumb range of motion (radial and volar abduction) measured by a blinded assessor

  7. Strength

    Time frame: at 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.

    Grip strength and pinch strength measured by a blinded assessor

  8. Migration of prosthesis on cone beam computed tomography

    Time frame: at 6 months and 1, 2, 5 and 10 years (with a 1-week reference scan).

    • Long-term radiological assessment with CBCT in the arthroplasty group to assess implant position, migration and loosening and to assess metacarpal 1 migration in the trapeziectomy group

Study contacts

Contact information is provided by the study sponsor or research team.

Joakim Stromberg, Md,PhD

CONTACT

[email protected]

+46768341327

Victoria Wängberg, MD

CONTACT

[email protected]

+46739804631

Sponsors and collaborators

Lead sponsor

Sahlgrenska University Hospital

Other

Collaborators

  • Vastra Gotaland Region

Registry information

Acronym: T3

Important dates

Study start
2026
Primary completion
2028
Study completion
2038
First posted
Apr 27, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.